The authors concluded that leronlimab, combined with carboplatin, was well tolerated at each dose level and that leronlimab showed early evidence of anti-tumor activity in CCR5+ metastatic triple-negative breast cancer patients [111]. In that regard, two out of ten patients achieved a confirmed partial response. Six of the ten patients achieved stable disease